Stephen Reeders
Founder & Managing Partner @ MVM Life Science Partners
Stephen Reeders is a Series C investor at MVM Life Science Partners focused on Biotechnology and Health Care. Steve Reeders founded MVM in 1997. Prior to setting up MVM, he was responsible for early-stage healthcare investments at Saunders, Karp & Megrue in New York City. Between 1988 and 1993 Steve was an Investigator of the Howard Hughes Medical Institute at the Boyer Center for Molecular Medicine at Yale, where he was also an Associate Professor ofMedicine and Genetics. He has published more than 50 papers on the molecular genetics of human disease.Steve has been involved in starting several US biotechnology companies and was acting CEO at UpToDate In Medicine in Wellesley, Mass. He practised medicine at the John Radcliffe Hospital, Churchill Hospital, Guys Hospital, St Thomas's Hospital, Hammersmith Hospital and the Institute of Neurology, Queen Square before taking up research into molecular genetics at Oxford University. He has a degree in Natural Sciences from Cambridge and a Doctorate in medicine from Oxford and is a member of the Royal College of Physicians of England.Steve is a member of the boards of Beacon Endoscopic Ltd, Cheetah Medical, Inc., and Pulmagen Therapeutics Ltd. He was previously a director of BioVex Group, Inc., Biomedix, Inc., Cara Therapeutics, Inc., Clavis Pharma ASA, Domantis Ltd, Gendaq Ltd, Momenta Pharmaceuticals, Inc., New Chemical Entities, Inc., Nova Science Ltd, Sangamo Biosciences, Inc., Spherics, Inc., UpToDate, Inc. Xention Ltd and Vascular Pathways, Inc.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Stephen Reeders invests in
Stages Stephen Reeders invests in
Countries Stephen Reeders invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (63%)
- Health Care 4 (50%)
- Medical 3 (38%)
- Medical Device 3 (38%)
- Therapeutics 2 (25%)
Stage
- Series C 5 (63%)
- Funding Round 2 (25%)
- Series B 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| OSSIO is an orthopedic fixation company committed to transforming the orthopedic experience for patients, physicians, and payors. Their vision is to provide the first credible replacement to metal implants in the $10B+ orthopedic fixation market (screws, pins, plates) with an Intelligent Bone Regeneration Technology. OSSIOfiber represents abreakthrough material platform for orthopedic and podiatric surgeons who seek a more biologically friendly way to restore patient stability and mobility with nothing permanent left behind.Founded in 2014, OSSIO began as the culmination of years of biomechanical research and a vision for the possibility of better bone healing. The technological basis of OSSIOfiber™ was developed and would lay the groundwork for ushering in a new breakthrough category of non-permanent fixation, “Bio-Integratives” hardware that has both desired strength AND bio-friendliness. Hardware that has the mechanical strength for easy insertion and secure fixation, while enabling the body to regrow bone, incorporating and replacing the implant (without the adverse inflammation and weakness often seen in “bio-resorbables and other “bio-composites”), has remained elusive to the industry until now. | $38.5M / Series C / Oct 17, 2022 | ||
| VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatientsettings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. | $38M / Series C / Oct 31, 2017 | ||
| Vascular Pathways, founded by Amir Belson, M.D., is a privately held medical device company focused on commercializing the Rapid IntraVascular Start (RIVS) catheter, an FDA cleared device enabling rapid, safe and successful peripheral IV insertion. | $14M / Series B / Nov 01, 2010 | ||
| Cara Therapeutics is an emerging biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation. Cara possesses both near-term clinical development opportunities combined with proprietary approaches to developing first-in-class novel therapeutics. Cara's most advanced patentedcompound, CR845, is currently undergoing clinical testing for acute pain and pruritis. This best-in-class compound possesses unique analgesic and anti-inflammatory activities appropriate for multiple therapeutic applications. In addition, Cara aims to develop a future pipeline of first-in-class molecules at novel analgesic and anti-inflammatory targets using its proprietary drug screening technology. | $24M / Series C / Nov 28, 2006 | ||
| As of August 4, 2008, Spherics, Inc. went out of business. Spherics, Inc., a pharmaceutical company, engages in developing and manufacturing oral pharmaceutical products for central nervous system conditions, gastrointestinal disorders, and cancer. It develops oral systems based on the application of bioadhesive polymers to oral dosage forms. Thecompany also provides products for neurological disorders, such as Alzheimer's, Parkinson's, and multiple sclerosis, as well as for stroke, epilepsy, chronic pain, and migraine. The company was founded in 1997 and is headquartered in Mansfield, Massachusetts. | $26.4M / Series C / May 13, 2005 | ||
| Spherics develops proprietary bioadhesive encapsulation technologies to improve the oral absorption of small molecule drugs. | $26.4M / Series C / May 12, 2005 | ||
| Beacon Endoscopic (BE) is a Boston based medical device company innovating in existing interventional endoscopic procedures and developing next generation devices to change the paradigm of surgery | $8M | ||
| VitalConnect develops wearable biosensor technology designed for wireless patient monitoring. It leverages extensive expertise in biomedical engineering, data analytics, chip design, and mobile and cloud software to create technology that supports decision-making paradigms. The company's products are designed for inpatient and outpatientsettings, such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. | $100M |
Co-Investors
MVM manages four funds totaling more than US$700 million. MVM has invested in biopharmaceuticals, diagnostics, drug delivery, gene therapy, healthcare services, medical devices, OTC medicines, research tools and vaccines.
MVM Life Science Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Anna Norrington
Head of Investor Communications
|
|||
Hugo Harrod
Partner
|
|||
Neil Akhurst
Finance Partner
|
|||
Stephen Reeders
Founder & Managing Partner
|
|||
|
Stephen Reeders
Founder & Managing Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Stephen Reeders invest in?
Stephen Reeders invests primarily in Biotechnology, Health Care and Medical startups, most often at Series C and Funding Round stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Stephen Reeders?
Public channels for Stephen Reeders include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Stephen Reeders last invest?
The most recent investment recorded for Stephen Reeders closed in Oct 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
